Apollo Life Sciences to Raise $9.5 Million via ASX Listing

Australian-based biopharmaceutical company Apollo Life Sciences Ltd lodged its prospectus with ASIC to raise $9.5 million in a June Initial Public Offer, underwritten by Blackwood Capital. Apollo Life Sciences is creating, manufacturing and marketing next-generation therapeutics based on the use of human proteins - biologics - to protect and improve human health. Apollo's proteins can be used to treat a range of disorders associated with disease and ageing, such as psoriasis, hepatitis C, rheumatoid arthritis, multiple sclerosis and Alzheimer's disease.

()a href="http://www.biospace.com/news_story.cfm?StoryID=20202520&full=1" target="_blank">BioSpace